| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 12.1 | 8.9 |
| Gross profit | 7.1 | 5.6 |
| Profit before tax | -7.5 | -5.9 |
| Net income | -7.5 | -5.9 |
| EPS (diluted, $ a share) | $-0.24 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +36.3% |
|---|---|
| Gross margin | 58.5% |
| Operating margin | -52.4% |
10-Q filed with the SEC, NASDAQ: CLPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ClearPoint Neuro, Inc.: key numbers
- Share price
- $8.30Close, Nov 16
- Market cap
- $266M
- Shares outstanding
- 32.05MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ClearPoint Neuro, Inc.
All →ClearPoint Neuro Financial Results
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, a 36% year-over-year increase driven by strong growth in neurosurgery navigation and therapy. The company raised its full-year 2026 revenue guidance to a range of $48.0 million to $50.0 million and reported a cash balance of $46.2 million.
“The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth. The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRAflow product integration has enabled improved operating leverage.”
Joe Burnett, President and CEO at ClearPoint Neuro